Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, has appointed James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O’Connell, Chief Executive Officer.   Doherty’s responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and r...